Institutional members access full text with Ovid®

Use of Intraoperative Radiotherapy for Upper-extremity Soft-tissue Sarcomas: Analysis of Disease Outcomes and Toxicity

Call, Jason A. MD; Stafford, Scott L. MD; Petersen, Ivy A. MD; Haddock, Michael G. MD

American Journal of Clinical Oncology: February 2014 - Volume 37 - Issue 1 - p 81–85
doi: 10.1097/COC.0b013e31826b9b3d
Original Articles: Soft Tissue

Objectives: To review outcomes for patients who received intraoperative radiotherapy (IORT) for upper-extremity sarcoma.

Methods: We identified patients with upper-extremity tumors who were treated with external beam radiotherapy, surgery, and IORT, with or without chemotherapy. Kaplan-Meier estimates for overall survival (OS), central control (CC), local control (LC), and distant control (DC) were obtained.

Results: Sixty-one patients were identified. Median age was 50 years (range, 13 to 95 y). Median follow-up was 5.9 years. Eleven patients had gross (R2; n=1) or microscopic (R1; n=10) disease at the time of IORT. IORT doses ranged from 7.50 to 20.00 Gy. External beam radiotherapy doses ranged from 19.80 to 54.00 Gy. OS at 5 and 10 years was 72% and 58%, respectively. LC at 5 and 10 years was 91% and 88%, respectively. DC at 5 and 10 years was 80% and 77%, respectively. Patients treated for recurrent disease had inferior 5-year OS compared with patients with first diagnoses (63% vs. 74%; P=0.02) and lower 5-year LC (67% vs. 94%; P<0.01). For patients with R1 or R2 resections, LC at 5 and 10 years was 100% and 86%, respectively; for patients with R0 resections, LC was 89% at both 5 and 10 years (P=0.98). Severe toxicity attributable to treatment was noted for 4 patients (7%).

Conclusions: For upper-extremity sarcoma, treatment including IORT was associated with excellent LC, limb preservation, and survival. LC rates were excellent for patients with positive margins after resection. Patients with recurrent disease had worse outcomes, but limb preservation was achievable for most patients.

Department of Radiation Oncology, Mayo Clinic, Rochester, MN

The authors declare no conflicts of interest.

Reprints: Michael G. Haddock, MD, Department of Radiation Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail:

© 2014 by Lippincott Williams & Wilkins, Inc